Table 2.

Treatment-emergent adverse events during the first 6 months (safety population)^a

Adverse event preferred term, n (%)b	DEX (n = 129)	Sham (n = 130)
IOP increased	38 (29.5)	4 (3.1)
Conjunctival hemorrhage	24 (18.6)	5 (3.8)
Conjunctival hyperemia	17 (13.2)	6 (4.6)
Visual acuity reduced	4 (3.1)	6 (4.6)
Conjunctival edema	4 (3.1)	1 (0.8)
Ocular hypertension	4 (3.1)	0 (0)
Eye pain	3 (2.3)	3 (2.3)
Headache	3 (2.3)	1 (0.8)
Vitreous hemorrhage	0 (0)	3 (2.3)

DEX dexamethasone intravitreal implant, IOP intraocular pressure

^aAll treatment-emergent adverse events reported in >2% of patients in either treatment group are listed

^bAdverse events were categorized for analysis using MedDRA version 17.0 preferred terms